Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket trial, including most of the cancer with CCR5 indicators.
Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases to liver and lung in preclinical study
Quick facts: CytoDyn Inc.
Price: 6.08 USD
Market Cap: $3.16 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE